Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2519991 | 1.00 | ALDH1A1 (0.54) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL26890594 | 0.92 | ALDH1A1 (0.54) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL25433999 | 0.91 | ALDH1A1 (0.53) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL25434818 | 0.88 | ALDH1A1 (0.50) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL30502815 | 0.86 | PKM (0.47) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL2520783 | 0.86 | PKM (0.47) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL31217219 | 0.86 | ALDH1A1 (0.47) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL30502819 | 0.86 | PKM (0.47) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL25433441 | 0.84 | ALDH1A1 (0.54) | ALDH1A1LMNAMEN1KMT2AHTT | |
| SCHEMBL25434397 | 0.83 | ALDH1A1 (0.56) | ALDH1A1LMNAMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4709729-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | Jazz Pharmaceuticals Ireland Ltd. (IE) | 2026-03-18 | — | — | EP | disclosed |
| EP-4680609-A1 | KRAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2026-01-21 | — | — | EP | disclosed |
| EP-4626888-A1 | COMPOUNDS | Redx Pharma Limited (GB) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025106901-A1 | COMBINATION CANCER THERAPIES WITH A KRAS MODULATOR AND AN RTK-MAPK PATHWAY INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| WO-2025106905-A1 | COMBINATION THERAPIES WITH A KRAS MODULATOR AND AN IMMUNOMODULATOR INHIBITOR | QUANTA THERAPEUTICS, INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| EP-4532494-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2025-04-09 | — | — | EP | disclosed |
| WO-2025034919-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2025034883-A1 | COMBINATION THERAPIES WITH KRAS MODULATORS | QUANTA THERAPEUTICS, INC. (US) | 2025-02-13 | — | — | WO | disclosed |
| EP-4475956-A1 | KRAS MODULATORS AND USES THEREOF | Quanta Therapeutics, Inc. (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2024236452-A1 | PYRAZOLO[4,3-F]QUINAZOLINE DERIVATIVES AS MODULATORS OF G12D MUTANT KRAS USEFUL FOR THE TREATMENT OF CANCER | JAZZ PHARMACEUTICALS IRELAND LTD. (IE) | 2024-11-21 | — | — | WO | disclosed |
| WO-2024192424-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2024-09-19 | — | — | WO | disclosed |
| WO-2024115890-A1 | COMPOUNDS | REDX PHARMA PLC (GB) | 2024-06-06 | — | — | WO | disclosed |
| WO-2023230190-A1 | PYRIMIDINE BASED MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-11-30 | — | — | WO | disclosed |
| WO-2023154766-A1 | KRAS MODULATORS AND USES THEREOF | QUANTA THERAPEUTICS, INC. (US) | 2023-08-17 | — | — | WO | disclosed |